Colorectal and other GI cancers:
Indications for: Mitomycin
Disseminated adenocarcinoma of the stomach.
Adult Dosage:
Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.
Children Dosage:
Not recommended.
Mitomycin Contraindications:
Thrombocytopenia. Coagulation disorders. Bleeding tendencies.
Mitomycin Warnings/Precautions:
Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.
Mitomycin Classification:
Cytotoxic antibiotic.
Mitomycin Interactions:
Caution with vinca alkaloids, other chemotherapy.
Adverse Reactions:
Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.
Note:
Formerly known under the brand names Mitozytrex, Mutamycin.
How Supplied:
Contact supplier.
Pancreatic, thyroid, and other endocrine cancers:
Indications for: Mitomycin
Disseminated adenocarcinoma of the pancreas.
Adult Dosage:
Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.
Children Dosage:
Not recommended.
Mitomycin Contraindications:
Thrombocytopenia. Coagulation disorders. Bleeding tendencies.
Mitomycin Warnings/Precautions:
Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.
Mitomycin Classification:
Cytotoxic antibiotic.
Mitomycin Interactions:
Caution with vinca alkaloids, other chemotherapy.
Adverse Reactions:
Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.
Note:
Formerly known under the brand names Mitozytrex, Mutamycin.
How Supplied:
Contact supplier.
